Imhoff John E's Form 4 filing
Guided Therapeutics Inc (GTHP) · filed Dec 20, 2024
- Accession no.
- 0001477932-24-008256
- Filed
- Dec 20, 2024
- Trade date
- Dec 18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Imhoff John ECIK 0001348439 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Common Stock | PPurchaseAcquired | +1,615,385 | –F1 | – | 8,727,444 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Common Stock | PPurchaseAcquired | +1,615,385 | –F1 | – | 1,615,385 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.